Novo Nordisk A/S: Novo Nordisk and Omeros announce asset purchase and license agreement for ...

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in up ...

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) ...